Amedisys (AMED): Revenue Not OpEx Tells The Story - Jefferies
- Wall Street lower as oil snaps four-day rally
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
- Twitter (TWTR) Engagement Appear to be Improving and MAUs are Solid - Analyst
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Jefferies analyst, Brian Tanquilut, reiterated his Buy rating on shares of Amedisys (NASDAQ: AMED) but cut his price target to $50 from $59 after a pre-release of weak Q3 EPS.
While pressuring earnings growth and price targets, the misstep seems mostly attributable to disruptions related to the rollout of its new IT system. While the EPS miss is disappointing, reported revenues were actually above consensus, highlighting strength in hospice and personal care. Beyond Q3, the analyst believes the company remains positioned to see healthy organic volume growth and margin expansion once its HCHB rollout is completed at year-end, which sets the stock up for good EPS growth going forward.
Shares of Amedisys closed at $42.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Raises Price Target on Bob Evans Farms (BOBE) Following 2Q EPS Beat
- Envision Healthcare (EVHC): Cutting PT But Staying Bullish - Jefferies
- AutoZone (AZO) Tops Q1 EPS by 5c; Comps Light of Views
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!